This study was initiated to evaluate the role of cfDNA‐NGS not only for the detection of ALK fusions and resistance mutations, but also for assessing prognosis and monitoring the dynamic changes of genomic alterations in ALK positive NSCLC patients treated with ALK TKIs in prospective manner. The gene discussed is ALK; the disease is non-small cell lung carcinoma.